Prevention and Control of Seasonal Influenza with Vaccines
Top Cited Papers
- 26 August 2016
- journal article
- practice guideline
- Published by Centers for Disease Control MMWR Office in MMWR. Recommendations and Reports
- Vol. 65 (5), 1-54
- https://doi.org/10.15585/mmwr.rr6505a1
Abstract
This report updates the 2015-16 recommendations of the Advisory Committee on Immunization Practices (ACIP) regarding the use of seasonal influenza vaccines (Grohskopf LA, Sokolow LZ, Olsen SJ, Bresee JS, Broder KR, Karron RA. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices, United States, 2015-16 influenza season. MMWR Morb Mortal Wkly Rep 2015;64:818-25). Routine annual influenza vaccination is recommended for all persons aged ≥6 months who do not have contraindications. For the 2016-17 influenza season, inactivated influenza vaccines (IIVs) will be available in both trivalent (IIV3) and quadrivalent (IIV4) formulations. Recombinant influenza vaccine (RIV) will be available in a trivalent formulation (RIV3). In light of concerns regarding low effectiveness against influenza A(H1N1)pdm09 in the United States during the 2013-14 and 2015-16 seasons, for the 2016-17 season, ACIP makes the interim recommendation that live attenuated influenza vaccine (LAIV4) should not be used. Vaccine virus strains included in the 2016-17 U.S. trivalent influenza vaccines will be an A/California/7/2009 (H1N1)-like virus, an A/Hong Kong/4801/2014 (H3N2)-like virus, and a B/Brisbane/60/2008-like virus (Victoria lineage). Quadrivalent vaccines will include an additional influenza B virus strain, a B/Phuket/3073/2013-like virus (Yamagata lineage).Recommendations for use of different vaccine types and specific populations are discussed. A licensed, age-appropriate vaccine should be used. No preferential recommendation is made for one influenza vaccine product over another for persons for whom more than one licensed, recommended product is otherwise appropriate. This information is intended for vaccination providers, immunization program personnel, and public health personnel. Information in this report reflects discussions during public meetings of ACIP held on October 21, 2015; February 24, 2016; and June 22, 2016. These recommendations apply to all licensed influenza vaccines used within Food and Drug Administration-licensed indications, including those licensed after the publication date of this report. Updates and other information are available at CDC's influenza website (http://www.cdc.gov/flu). Vaccination and health care providers should check CDC's influenza website periodically for additional information.Keywords
This publication has 403 references indexed in Scilit:
- The safety and efficacy of live attenuated influenza vaccine in young children with asthma or prior wheezingEuropean Journal of Clinical Microbiology & Infectious Diseases, 2012
- A randomized, double-blind noninferiority study of quadrivalent live attenuated influenza vaccine in adultsVaccine, 2011
- Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok®) against influenza in healthy adults: A randomized, placebo-controlled trialVaccine, 2011
- Evaluation of the safety, reactogenicity and immunogenicity of FluBlok® trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50–64 years of age☆Vaccine, 2011
- Impact of maternal immunization on influenza hospitalizations in infantsAmerican Journal of Obstetrics and Gynecology, 2011
- Critically Ill Patients With 2009 Influenza A(H1N1) Infection in CanadaJAMA, 2009
- The Evolutionary Dynamics of Human Influenza B VirusJournal of Molecular Evolution, 2008
- Safety and Immunogenicity of a Baculovirus-Expressed Hemagglutinin Influenza VaccineJAMA, 2007
- Influenza-Associated Hospitalizations in the United StatesJAMA, 2004
- Cocirculation of two distinct evolutionary lineages of influenza type B virus since 1983Virology, 1990